资讯
Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.
The ICR and The Royal Marsden are internationally renowned for our work together to conduct early- and late-phase clinical trials. Our joint Drug Development Unit, which sees around 300 patients per ...
Our leadership teamProfessor Kristian Helin Chief Executive and President The Chief Executive is responsible to the Board of Trustees for the overall direction of the ICR’s management, research and ...
Cell biologists have made a significant advance, uncovering the key role of an enzyme in determining the physical structure and behaviour of cancer cells, including how they spread. The enzyme, called ...
Scientists have discovered clues which may explain why some treatments stop working for people with bowel cancer – causing around 16,800 deaths in the UK every year. The study, led by researchers at ...
Blood cancer causes different types of blood cells grow uncontrollably, crowding out healthy blood cells and making it harder for the body to fight infections or heal wounds. It falls into these three ...
The Institute of Cancer Research Where we make the discoveries that defeat cancer We are a world-leading cancer research institute, a charity, and a member institution of the University of London.
Scientists have developed a tool that can predict how bowel cancer adapts to treatment – helping researchers to design new personalised drugs that will keep patients living well for longer. A team ...
Scientists have discovered clues which may explain why some treatments stop working for people with bowel cancer – causing around 16,800 deaths in the UK every year. The study, led by researchers at ...
Thousands of patients with a common type of blood cancer could benefit from a new drug combination, while others could see their disease kept at bay for longer. Research published in the journal Blood ...
An immunotherapy helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found. Pembrolizumab kept cancer at bay for some patients for an ...
News from ASCO 2025 From 30 May to 3 June, the world’s leading oncologists and researchers, including scientists from The Institute of Cancer Research, London, will converge at the 2025 American ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果